Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Issue 2

Metastatic Castration-Resistant Prostate Cancer Issue 2

The efficacy of radium-223 was not impacted by prior treatment with an androgen receptor inhibitor for men with bone metastatic castration-resistant prostate cancer.

James M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.

In the first phase III trial to show a benefit for adjuvant therapy in prostate cancer, treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival (OS) rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.

Metastatic Castration-Resistant Prostate Cancer